SecBot SecBot
8-K ·Filed Jul 16, 2026

HRMY

Harmony Biosciences Holdings, Inc.
BULLISH
Impact 7/10
Horizondays Processed4mo ago SEC0001104659-26-084095
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The revenue pre-announcement is clearly positive and likely to drive the stock higher on the session. However, the abrupt CFO departure after only 3 months introduces execution risk and may cap upside. Traders should watch for the full Q2 earnings report on August 4 for EPS, margins, and pipeline updates. The interim CFO appointment provides continuity but a permanent CFO search is underway.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$33.53
T+0 close · Jul 16, 2026 · via day close
Latest settled
+14.82%
T+20 · $38.50
Vs SPY
+11.20%
α at T+20
Next horizon
T+60
due 6w ago
  1. T+0 · Jul 16 $33.53entry
  2. T+1 · 4mo ago +0.72%α +1.71% · $33.77
  3. T+5 · 4mo ago +6.77%α +8.44% · $35.80
  4. T+20 · 3mo ago +14.82%α +11.20% · $38.50
  5. T+60 · due 6w ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Harmony Biosciences pre-announced record Q2 2026 WAKIX net product revenue of ~$261M (+30% YoY), reaffirmed full-year guidance of $1.0B-$1.04B, and disclosed the immediate departure of CFO Glenn Reicin (hired only ~3 months ago) with the controller appointed as interim CFO. The revenue beat is strongly positive, but the abrupt CFO departure introduces governance uncertainty that partially offsets the bullish signal.

Key Financial Metrics

Revenue
$261.0M
est $242.1M · +7.8% · +30.0% YoY
Guidance
$1.0B-$1.04B
maintained

Key Facts

  • Q2 2026 preliminary WAKIX net product revenue of ~$261M, a record quarter, representing 30% YoY growth and 21% sequential growth over Q1 2026
  • Reaffirmed full-year 2026 net product revenue guidance of $1.0B to $1.04B
  • CFO Glenn Reicin stepped down effective July 16, 2026 to pursue other opportunities; employed only since April 14, 2026 (~3 months)
  • Stephen Mollichella, SVP & Controller, appointed Interim Principal Financial Officer
  • Full Q2 2026 financial results to be reported on August 4, 2026
  • Separation agreement provides Reicin $500K severance over 12 months plus $62,500 lump sum and benefits
  • Company states departure is not due to any disagreement with operations, policies, or practices

Financial Impact

Q2 2026 revenue of ~$261M vs consensus estimate of $242.1M represents a ~7.8% beat; 30% YoY growth significantly above the 17% growth rate reported in Q1 2026

revenueguidance

Risk Factors

  • CFO departure after only 3 months raises questions about internal stability and may signal undisclosed issues
  • Preliminary revenue only, full P&L with EPS, margins, and cash flow details not yet available
  • Guidance maintained but not raised despite strong Q2 beat, suggesting management sees potential headwinds in H2

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
65% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-084095
Document: hrmy-20260716x8k.htm0001104659-26-084095
Document: hrmy-20260716xex99d1.htm0001104659-26-084095
Document: 0001104659-26-084095-index-headers.html0001104659-26-084095
Document: 0001104659-26-084095-index.html0001104659-26-084095
Document: 0001104659-26-084095.txt0001104659-26-084095
8-K Data (Synthetic)0001104659-26-084095

US Market Status

Market Closed · Opens in 7h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 16, 2026